Corbus Pharmaceuticals Holdings (CRBP) EBITDA Margin (2015 - 2021)
Corbus Pharmaceuticals Holdings (CRBP) recorded quarterly EBITDA Margin of 2239.62% in Q3 2021, up 82.13% quarter-over-quarter from 12533.18% in Q2 2021, and up 59597.0% on a YoY basis from N/an in Q3 2020.
Corbus Pharmaceuticals Holdings (CRBP) EBITDA Margin (2015 - 2021) Analysis & Trends
Corbus Pharmaceuticals Holdings' EBITDA Margin history runs 7 years deep, the most recent figure standing at 2239.62% for Q3 2021.
- In Q3 2021, EBITDA Margin rose 59597.0% year-over-year to 2239.62%; the TTM figure through Jun 2022 stood at 35881.58% (down 3350157.0% YoY), while the FY2021 annual figure was 6350.09%, down 389388.0% from the prior year.
- EBITDA Margin was 2239.62% for Q3 2021 at Corbus Pharmaceuticals Holdings, up from 12533.18% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 95.17% in Q4 2019 to a low of 13307.44% in Q2 2020.
- Historically, EBITDA Margin has averaged 3050.93% across 5 years, with a median of 1429.2% in 2018.
- The sharpest annual moves came in 2019 and 2020: EBITDA Margin surged 884691 bps in 2019, then slumped 1331330 bps in 2020.
- A 5-year view of EBITDA Margin shows it stood at 873.63% in 2017, then slumped by 902 bps to 8751.74% in 2018, then jumped by 101 bps to 95.17% in 2019, then sank by 1371 bps to 1209.33% in 2020, then slumped by 85 bps to 2239.62% in 2021.
- The last three EBITDA Margin figures came in at 2239.62% (Q3 2021), 12533.18% (Q2 2021), and 2484.31% (Q1 2021), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Corbus Pharmaceuticals Holdings | 133.67 Mn | 105.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | -2,239.62% |
| Jun 30, 2021 | -12,533.18% |
| Mar 31, 2021 | -2,484.31% |
| Dec 31, 2020 | -1,209.33% |
| Sep 30, 2020 | -2,835.59% |
| Jun 30, 2020 | -13,307.44% |
| Mar 31, 2020 | -1,683.08% |
| Dec 31, 2019 | 95.17% |
| Sep 30, 2019 | -969.07% |
| Jun 30, 2019 | 5.86% |
| Mar 31, 2019 | -1,406.53% |
| Dec 31, 2018 | -8,751.74% |
| Sep 30, 2018 | -1,365.69% |
| Jun 30, 2018 | -1,451.86% |
| Mar 31, 2018 | -1,248.36% |
| Sep 30, 2017 | -873.63% |
| Jun 30, 2017 | -2,082.20% |
| Mar 31, 2017 | -576.07% |
| Sep 30, 2016 | -718.30% |
| Jun 30, 2016 | -1,056.90% |